Brief Summary
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Protocol Interventions
Drug: Peluntamig (PT217), Drug: Carboplatin + Etoposide, Drug: Atezolizumab